Shionogi

aka Shionogi & Co., Ltd., 塩野義製薬, TSE:4507

Shionogi is a long-established Osaka pharmaceutical company, best known for antibiotics and antivirals, that developed the platinum chemotherapy nedaplatin sold in Japan as Aqupla.

Shionogi, founded in Osaka in 1878, is a research-based pharmaceutical company with strengths in infectious disease, including the antiviral Xofluza and the antibiotic cefiderocol, and in pain and central nervous system medicines. In oncology it developed nedaplatin (254-S), a second-generation platinum agent with less kidney toxicity than cisplatin, approved in Japan in 1995 as Aqupla for head and neck, lung, oesophageal, bladder, cervical, ovarian and testicular cancers.

Headquarters

Osaka, JP

Scorecard

All companies

#217of 1181 companies, score 21

modalities +2
registry trials +19

0 approved, 0 in phase 3, 0 earlier, 0 targets, 92 registry studies. Formula on the scorecards page.

Type

pharma · TSE:4507

Stage

Public

Website

www.shionogi.com/

Founded

1878

Products

1top

EstablishedSecond-generation platinum cytotoxic, intravenous

Nedaplatin · Aqupla

Nedaplatin is a Japanese platinum drug, approved there in 1995, used for head and neck, oesophageal, lung, cervical and other squamous cancers as a gentler alternative to cisplatin on the kidneys; it has never been approved in the West.

Connected